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Diffusion imaging has been instrumental in understanding damage to the central 
nervous system thanks to its sensitivity to microstructural changes. Clinical 
applications of diffusion imaging have grown exponentially over the past couple 
of decades in many neurological and neurodegenerative diseases such as 
Multiple Sclerosis (MS). For several reasons, MS has been extensively researched 
using advanced neuroimaging techniques, which makes it an “example disease” 
to illustrate the potential of diffusion imaging for clinical applications. In 
addition, MS pathology is characterised by several key processes competing with 
each other, such as inflammation, demyelination, remyelination, gliosis and 
axonal loss, enabling the specificity of diffusion to be challenged. In this review 
we will describe how diffusion imaging can be exploited to investigate micro-, 
meso- and macro-scale properties of the brain structure and discuss how they 
are affected by different pathological substrates.  Conclusions from literature are 
that larger studies are needed to confirm exciting results from initial 
investigations, before current trends in diffusion imaging can be translated to the 
neurology clinic. Also, for a comprehensive understanding of pathological 
processes it is essential to take a multiple-level approach where information at 






Diffusion MRI (dMRI) is sensitive to the hindrance of diffusion by tissue 
microstructure, and thus provides an indirect measure of the size, orientation 
and shape of cellular structures in vivo1. This makes dMRI unique in its ability to 
provide microstructural information non-invasively. Ever since the introduction 
of diffusion tensor imaging (DTI)2 the scalar indices derived from the tensor, 
such as mean diffusivity (MD), which quantifies the magnitude of diffusion 
within a voxel, and fractional anisotropy (FA)3, which measures the 
directionality of diffusion, have been applied to a wide range of neurological and 
psychiatric disorders. 
 
The sensitivity of dMRI to the microscopic translational motion of water 
molecules is also reflected into its sensitivity to the principal direction of 
diffusion, which can be assumed to coincide with that of the underlying white 
matter fibers (at least for voxels comprising of a single major fibre bundle). This 
forms the basis for diffusion ‘tractography’4 a method able to produce 3D 
‘reconstructions’ of probable white matter pathways that offer a reasonable 
representation of anatomy.  
 
Recently the possibility to reconstruct white matter connections using diffusion 
tractography has been combined with network analysis and graph theory, to 
form an integral part of “connectomics”, a science branch aiming at mapping all 
neural connections within the central nervous system (CNS), i..e the brain 
connectome5,6. 
 These features make dMRI a technique sensitive to all scales, ranging from the 
microscopic properties of tissue to the connections that can be mapped at 
specific network (mesoscopic) or whole-brain (macroscopic) level7.  
 
While DTI has proven sensitive to subtle brain abnormalities, its translation into 
clinical routine (other than for the diagnosis of acute stroke8,9) has been limited. 
To be of real clinical added value, a biomarker would have to provide 
information more specific than what already available through conventional 
imaging (i.e. identifying lesional tissue). The lack of specificity, or, in other words 
the inability to link patterns of diffusion abnormalities with specific pathological 
substrates, may have contributed to a limited adoption into the clinical setting of 
DTI. Attempts to address this issue have led to the development of a series of 
frameworks that are either model-free or employ higher order models of 
diffusion, with a more direct interpretation of model parameters in terms of their 
potential biological substrate10. The downside of this approach is the increased 
mathematical complexity of such models, which makes their adoption in clinical 
settings difficult. 
 
With the aim to review the added value and the pitfalls of dMRI in clinical 
applications, here we will focus on multiple sclerosis (MS), and on the potentials 
of dMRI to clarify the effects of this disease on the brain at the micro-, meso- and 
macro-scopic scales.  MS was chosen as “example” disease, as its pathology is 
characterised by several key processes competing with each other, enabling the 
specificity of diffusion to be challenged. 
 Basic diffusion MRI concepts 
 
Details about dMRI methods and techniques are covered by several papers and 
book chapters, e.g.,11-13. Here we will simply introduce the parameters needed 
for understanding the subsequent discussion. 
 
Diffusion sensitization can be introduced by the use of pulsed magnetic field 
gradients played out in addition to the standard imaging gradients. The 
dephasing caused by the gradients results in signal attenuation proportional to 
the diffusion coefficient14.  The amount of diffusion sensitization, dependent on 
the amplitude, separation and duration of the gradients, is summarised by the b 
factor (or b value)1. The time allowed for the diffusion process encoding is 
referred to as the diffusion time tdiff and its definition depends on the pulse 
sequence used. Typically the acquisition is repeated several times varying the 
orientation and the amplitude of the gradients. The specific pattern used will 
depend on the application, the model to be fitted and the techniques used for 
image processing.  
 
Diffusion Tensor Imaging (DTI)2 is assuming that water diffusion in tissue can be 
associated with a diffusion tensor (DT) characterized by three eigenvalues 
(123) identifying the principal direction of diffusivity, and the corresponding 
three eigenvalues (123). From the eigenvalues it is possible to derive 
indices reflecting properties of the underlying tissue such as mean diffusivity 
(MD, average of the three eigenvalues), fractional anisotropy (FA, proportional to 
the variance of the eigenvalues)3, axial diffusivity (AD, equal to 1) and radial 
diffusivity (RD, equal to the average of2 and 3).  
 
Q-space imaging (QSI) is a model-free approach that attempts to provide a more 
accurate description of tissue microstructure and to overcome the limitations of 
DTI-derived indices such as FA and MD15,16. QSI relies on the acquisition of dMRI 
data at multiple b (or ‘q’, with q2 proportional to b/tdiff) values to sample the 
signal decay with q. The Fourier Transform of the signal curve gives the 
probability density function (PDF) of molecular diffusion. Three parameters, 
namely the root mean square displacement (RMSD), the probability for zero 
displacement (P0), and the kurtosis (K, i.e. a measure of deviation from Gaussian 
behaviour) can then be derived. If kurtosis is the parameter of interest, this can 
also be derived using diffusion kurtosis imaging (DKI), a simpler approach to 
characterize the non-Gaussianity of the probability distribution, less demanding 
in terms of data acquisition, although still requiring multiple b values17. DKI can 
provide parameters such as the mean kurtosis (DK), independent on the 
direction of observation, or the K// or K⊥, which are the kurtosis along and 
across the main eigenvector direction (as defined by the diffusion tensor). 
 
The appeal of directly measuring physical properties has prompted the 
development of models linking the dMRI signal directly to properties of tissue, 
such as the axon diameter, neurite density (ND) and orientation dispersion 
(OD)13,18-20. Such models are making assumptions to capture the influence of 
restriction and hindrance on water movement. The non-monoexponential decay 
of the diffusion signal at high b values suggests the presence of more than one 
water compartment with differing diffusion behaviours. In order to capture this 
compartmentalisation, quite a substantial number of models have been proposed 
over the years as shown by Ferizi et al.10, who have compared them head to head 
thanks to a rich dataset acquired with many diffusion weightings. Three 
compartment models seem to describe the signal decay at best and fit the data 
considerably better than the DT model.   
 
 
Multiple Sclerosis: a quick overview 
 
MS is an inflammatory condition affecting the CNS, and constitutes the greatest 
cause of non-traumatic disability in young adults in the Western world.  
 
The first MS episode is referred to as clinical isolated syndrome (CIS). Forty to 
sixty percent of patients presenting with CIS develop a clinically definite MS over 
the course of the years21. The most common MS phenotype is relapsing-remitting 
(RR) MS, characterized by recurring episodes of inflammation and demyelination 
(relapses) affecting one or more domains, including for example motor, visual 
and cognitive systems unpredictably. During a relapse typically the patient 
experiences acute symptoms, followed by complete or partial recovery. In the 
majority of patients, the relapses eventually become difficult to distinguish from 
each other, with a less clear recovery, and the patient enters a phase of 
progressively accumulating disability, referred to as secondary progressive 
multiple sclerosis (SPMS). In 10-15% of patients the clinical course is 
progressive from the onset and is referred to as primary progressive MS (PPMS).  
 
From a pathological point of view, MS is characterized by the presence of 
confluent demyelinated lesions in the white and grey matter of the brain, optic 
nerve and spinal cord. These lesions are caused by immune cell infiltration 
across the blood–brain barrier (BBB) that promotes inflammation, 
demyelination, gliosis and neuroaxonal degeneration, leading to disruption of 
neuronal signalling. Demyelinated areas in the white matter can be partially 
repaired by remyelination, although histological evidence of this process shows 
that the myelin sheath does not recover its original structural properties (e.g.  it 
is characterized by thinner layers and a redistribution of the sodium channels 
along the axonal membrane)22. While white matter lesions are visible on 
conventional T2-weighetd MRI, and BBB leakage can be detected with 
gadolinium-enhanced T1-weighetd MRI, the correlation between lesion volume 
and physical disability is moderate in RRMS, and modest at best in the 
progressive forms due to the complexity of the pathophysiology of MS23,24.  In 
addition, subtle damage is known to occur outside of visible lesions, in the so-
called normal-appearing white matter (NAWM) and grey matter (NAGM)25. This 
damage is primarily characterised by neuro-axonal loss, which ultimately results 
in impaired connectivity between different areas of the CNS and can explain 
patient disability better than macroscopic demyelinated lesions, particularly in 
SPMS26.  
 
It has been shown in several studies that inflammation, demyelination and 
axonal loss, while linked to each other, can also happen independently in MS27. 
Damage can also happen in white matter and grey matter separately, where grey 
matter atrophy may not be consistent with grey matter demyelination28.  Given 
the complexity of MS pathology, we believe that MS offers a good model for 
investigating whether dMRI can provide added value by offering quantitative 
indices to disentangle the mechanism of this disease, not captured by 
conventional imaging. Proposing novel imaging biomarkers at different scales, 
dMRI could potentially be more specific to the pathophysiological substrate of 
MS, while also being more sensitive to disease progression. 
 
Microscopic scale: insights about localised pathology 
DMRI offers a variety of tissue models that can be used to assess tissue 
microstructure, from the simplistic DTI model, to more complex mathematical 
representations that aim at providing biophysically meaningful indices, to 
model-free approaches requiring specialised acquisition schemes. A fundamental 
step required for any of the indices derived from these models to be adopted in 
clinical studies is that of validation, which can be achieved through simulations, 
animal models, post-mortem tissue and histological comparison. Here we 
attempt an overview of this enormous ever-growing field in order to provide the 
added value and limitations of such methods in MS. 
MS was one of the first clinical applications of dMRI, and more than 300 MS 
papers based on DTI have been published to date. The main outcomes can be 
summarised as follow: DTI parameters are abnormal within MS lesions, with 
typically increased diffusivity (mean, radial, and axial) and reduced anisotropy 
compared to the normal appearing white matter (NAWM)29,30. Examples of DTI 
indices in a patient with MS are shown in figure 1. These results are consistent 
with increased water content, loss of myelin and axons, and the presence of 
gliosis. Also, DTI parameters are sensitive to the substrate of lesional damage, as 
demonstrated by the large variability of DTI indices within lesions31. More 
interestingly, abnormal DTI parameter values are typically found in the NAWM 
of patients compared to age-matched healthy controls, consistent with subtle but 
widespread damage known to occur in MS. These initial findings have 
contributed to establish that white matter damage is widespread in MS even in 
the early phases, although they did not provide a clear definition of the substrate 
underpinning these abnormalities. The results obtained in the grey matter (GM) 
are more intriguing, particularly those obtained in the basal ganglia and the 
thalamus. Ciccarelli et al.32 were the first to report a paradoxical increase in FA in 
the caudate and putamen of patients with MS compared to controls, along with a 
reduction in the MD. The authors excluded that these findings could be caused by 
gliosis, which would have resulted in more disorganization (e.g. reduced 
anisotropy, increased T2) and attributed them to axonal degeneration due to 
fiber transection in remote focal MS lesions. Later, other authors reported 
increase of tissue anisotropy of the basal ganglia and the thalamus in RRMS and 
SPMS patients33,34 and its correlation with patients disability scores33-36 . The 
inability of MD and FA to distinguish and quantify co-existing inflammation, axon 
injury and myelin damage, however, limits its usefulness in understanding the 
mechanisms of MS. In particular, it was shown very early on that very different 
patterns of microstructural changes can result in the same amount of decreased 
anisotropy37. In order to address this limitation, some authors have looked at the 
additional information provided by the single eigenvalues, and in particular of 
“axial” and “radial” diffusivities38,39. While results in animal work supports the 
interpretation of AD as a marker for axonal injury and dysfunction, and of RD as 
proxy for myelin injury, generalising this interpretation can be dangerous and 
lead to the wrong conclusions40,41.  
(figure 1) 
As already mentioned, the DTI-derived indices are relatively “crude” and non-
specific; they are calculated on the assumption of a Gaussian probability density 
function for the diffusion of water molecules14. Several processes occurring at 
microstructural level, however, may affect the diffusion signal in unpredictable 
fashion, and their effect might not be accurately captured by Gaussian models. In 
this situation, model-free approaches (e.g. QSI and DKI introduced above) are 
preferable and can give parameters that are associated to biophysical properties 
of the underlying substrate. For example from QSI it is possible to estimate the 
full width half maximum (FWHM) of the probability distribution function, which 
is known to be strictly linked to axonal properties such as diameter42. QSI 
requires a large number of data points, and q values beyond those typically 
achievable in a clinical protocol.  For all these more complex approaches, 
acquisition time and diffusion scheme requirements are demanding, and not 
necessarily available on all clinical scanners. For these reasons, only a handful of 
clinical applications are available, and usually limited to pilot studies, 
demonstrating the sensitivity of these techniques to pathology. As for all novel 
imaging biomarkers, these methods require validation against histology. Q-space 
and DKI were applied in animal models and in post-mortem tissue to support 
studies in vivo in brain and spinal cord of healthy subjects and patients with MS. 
One of the most popular models of multiple sclerosis is experimental allergic 
encephalomyelitis (EAE), which induces inflammation and demyelination and is 
mainly induced at spinal cord level. EAE can be caused in different animal 
species43, and has been extensively used to study MS. 
 
A q-space analysis of EAE diseased swine spinal cords revealed abnormal 
displacement, probability and anisotropy values within macroscopic plaques 
(visible on T2-weighted scans), but also in the NAWM44. Direct comparison with 
histology confirmed that areas of abnormal q-space parameters overlapped with 
areas of pathology as assessed by hematoxylin and eosin, Luxol fast blue, and 
neurofilaments stains. However, this study did not provide a clear interpretation 
of these parameters in terms of myelin, axons or glial cells density.  
 
The first example of in-vivo QSI was applied in the brain of MS patients by Assaf 
et al. who measured q-space parameters in 13 MS patients and 6 healthy 
controls, using a region of interest approach. Comparing QSI with DTI, they 
showed that the former provides the highest sensitivity to subtle pathological 
changes in the NAWM45. Representative parametric maps reproduced from this 
paper are shown in Figure 2. Results of the study indicated that q-space FWHM 
was more sensitive to damage in the NAWM than DTI-derived indices (e.g. FA), in 
mild as well as severe cases of MS. The authors explained these findings as a 
consequence of the higher sensitivity of high b-value dMRI to the slow diffusing 
water molecules component of the signal, reflecting myelin integrity in white 
matter.  In the attempt to provide further insight into the substrate of these 
changes, the same Authors have further investigated NAWM with QSI, confirming 
their original findings and showing an association with MRS-derived markers of 
neuronal integrity46.   
 
(figure 2 approximately here) 
 
Spinal cord damage often correlates better with disability than brain damage in 
MS47, therefore efforts are dedicated to implementing novel imaging biomarkers 
in this structure too. Despite the difficulty of dMRI of the spinal cord, in vivo QSI 
investigations have been reported48-50. The reason for the success of QSI in the 
spinal cord is that it is possible to take advantage of the highly symmetric 
microstructure of spinal cord tissue compared to brain; in fact, in the spinal cord 
fibers are running parallel to its longitudinal axis, hence the acquisition protocol 
can be simplified by probing diffusion along just two orthogonal directions 
(along and across the spinal cord). These studies showed consistent results with 
brain findings, also indicating that the source of specific clinical symptoms might 
be explained by different biophysical substrates (i.e. RMSD and P0)49. 
 
Among q-space parameters, the diffusion kurtosis, K has received more attention 
than others in MS, especially because it has been associated with myelination51, 
as confirmed by studies in the spinal cord of marmosets with chemically induced 
demyelination, and in shiverer mice52,53. 
 
Consistently, recent reports based on DKI have demonstrated abnormal K values 
in both NAWM and NAGM of patients with MS54-56. Metrics along specific white 
matter tracts were shown to correlate with neuropsychological measures and 
evoked potentials57.  
 
While q-space and DKI offer the added value of increased sensitivity to 
pathological changes, correlating with some histological features, still they do 
not provide specific information about their nature. Ideally, more direct 
measurements of microstructure biomarkers, such as axonal density or radius 
are desirable.  In principle diffusion MRI can be exploited to infer this 
information, but typically these techniques require prohibitively long acquisition 
times and specialised equipment. Mathematical models of the behaviour of water 
diffusion in tissue propose an alternative to DTI and QSI.  
 
The specificity of parameters obtained from such models makes them ideal 
candidates for investigating the patholophysiology of MS. Nevertheless, to date 
there are no published papers reporting their application to MS populations, and 
therefore we can only speculate on their usefulness.  
One report using diffusion basis spectrum imaging (DBSI58), an approach that 
models axons as anisotropic diffusion tensors, and cells and extracellular space 
as isotropic diffusion tensors, demonstrated that each of the parameters derived 
from DBSI correlated with a distinct histological stain59 in post-mortem MS brain 
tissue.  Surprisingly, to date, other multi-compartments models developed with 
clinical scanners in mind, such as Neurite Orientation and Density Imaging 
(NODDI)13, have not been reported in vivo in MS yet.  
To date, the main contribution of dMRI to the characterisation of MS at the 
microscopic scale has been to provide biomarkers sensitive to subtle changes, 
invisible on conventional imaging. The ability to detect damage to the NAWM of 
both brain and spinal cord, as well as the ability to differentiate lesions that 
appear similar on T2-weighted MRI, but that are characterised by different 
substrates, are a clear advantage of dMRI over conventional imaging methods. 
Despite their potential added value in terms of microstructural specificity, due to 
lengthy acquisition times and the need for specialised acquisition and analysis, to 
date advanced methods have been explored only in small samples.  
 
Mesoscopic scale: insights into specific functional systems 
 
Understanding local properties of tissue microstructure that characterise local 
tissue alterations due to a disease sometimes may not be enough for explaining 
functional impairment. Therefore, it is important to place the local disruption 
within the context of the functional networks it affects as current correlation of 
clinical scores and conventional MRI, such as lesion load, is unsatisfactory and 
unspecific60.   
 
DMRI tractography enables the reconstruction of specific white matter bundles, 
by estimating the principal direction(s) of diffusion within a voxel. Once a tract 
has been segmented out with tractography, tract-specific measures such as 
volume, MD, FA, or other MRI parameters, can be estimated within the tract. This 
offers the unique opportunity to target pathways associated with specific 
functional impairments, and focus on clinically eloquent areas. Unsurprisingly, 
several groups investigating MS have focused on the sensory-motor system. Most 
studies included a quantification of tissue damage along the cortico-spinal tract 
(CST) as well as of the primary motor cortex (the latter usually obtained through 
estimation of atrophy or cortical thickness)61-63. MD, AD and RD of the CST were 
consistently found to be increased in MS patients compared to healthy controls, 
and associated to measures of functional impairment, such as the timed-walk 
test or the pyramidal functional system of the expanded disability status scale 
(EDSS) 62,63. FA was less significantly associated with disability62. One study that 
recruited patients with lesions within the CST showed that the surface area of 
the paracentral cortex was inversely correlated to the CST connectivity 
(estimated by probabilistic tractography) on the affected side, while the opposite 
was true for the unaffected side64. These results suggest the intriguing 
hypothesis that a lesion in the CST may cause plastic changes to the morphology 
of the primary motor cortex.  
 
A more sophisticated approach for studying functional systems relies on the use 
of graph theory6. According to this framework, each relevant grey matter area 
acts as a “node”, with various nodes connected by edges. The edges are the white 
matter connections and can be characterised by dMRI tractography. Topological 
scores can be used to evaluate measures of integration/segregation and 
efficiency of the network. Pardini et al.65 used graph theory to quantify a motor 
network efficiency score based on FA, tissue volume, and magnetization transfer 
ratio (MTR, proportional to myelin content66,67), which was shown to explain 
58% of the variation in EDSS in a group of 71 patients with MS. 
Other pathways have been studied with similar methodology, including the 
cingulum, with both its sections being associated with symptoms such as 
fatigue68, and episodic memory and speed of processing69. 
 This network approach is particularly interesting as it may help to clarify the 
frequent paradoxical observation of severe clinical symptoms against 
radiological evidence of relatively spared brain tissue60 A speculative 
explanation could be that when each single pathway within a functional system 
is only subtly affected by MS pathology (which could range from demyelination, 
to axonal loss or inflammation), the functional system impairment emerges only 
when the pathways alterations are combined at network level, ultimately 
resulting in dysfunction. In other words, the degree of damage of each edge is too 
modest to result in a significant difference with respect to healthy controls 
(Figure 3); however, if each single “edge” of the network is affected, graph 
metrics may be able to capture the abnormalities. This approach comes at the 
price of losing information about precise localisation of specific tissue damage.  
 
(Figure 3 approximately here) 
The added value of studying meso-scale properties of specific functional systems 
to capture impairment must be weighted against the well-known pitfalls of 
tractography70, which make an unsupervised use of such technique in the clinical 
setting challenging. 
 
Macroscopic scale: the brain as an integrated system 
 
The concept of white matter as the wiring that connects distinct functional areas 
can be generalised to describe the whole brain as a complex network. DMRI is 
currently the only technique able to map anatomical connectivity non-invasively, 
with the aim of defining the so-called “structural connectome”71. Examining the 
brain as an integrated network can provide new insights about large-scale 
neuronal communication and provides a platform to understand how brain 
connectivity relates to human behaviour, and how it may be altered in disease. 
This approach to investigating the brain is at the opposite end of the microscopic 
localised scale, far from closing the gap between imaging metrics and 
microscopy, but it is essential to understanding functional impairment and 
functional reserve.72,73 
 
A whole-brain network can be defined similarly to the system networks 
introduced above at the mescoscopic scale. It can be seen as an ensemble of 
neuronal elements, the “nodes”, between which some pairwise relationships 
(“links” or “edges”) can be defined. In the case of the structural connectome, 
typically the nodes are defined through the parcellation of the whole grey 
matter74 based on anatomical75, functional, or cyto-architectonic criteria76. 
Random parcels have also been used77, as well as data-driven approaches78. The 
links between these nodes are defined by the white matter connections, which 
are reconstructed by diffusion tractography. The links can be weighted using the 
number of reconstructed streamlines79, tract-specific dMRI indices80, or 
microstructural properties derived from other quantitative MRI techniques81. As 
for specific networks, graph theory provides a theoretical framework in which 
the topology of the network can be examined6. The power of this approach is in 
its ability to reduce a very complex structure into a handful of easily treatable 
summary measures. This is an emerging field that promise to complement more 
traditional approaches of investigating microscopic local properties.   
 Two independent studies82,83 demonstrated that in the early stages of MS the 
structural connectome is altered while the functional connectome is preserved, 
providing a new insight in the mechanisms of structural and functional 
derangement (Figure 4). Interestingly, this sequence of events seems to occur in 
the opposite direction to neurodegenerative disorders such as Alzheimer 
disease, where functional changes have been reported to precede structural 
ones84,85. A topological disruption of several sub-networks was also reported in 
relapsing remitting MS patients86, with reduced whole-brain network efficiency 
correlating with disability. These topological features ultimately define the 
vulnerability or resilience of the network to injuries.  Given the impact of white 
matter damage on the whole brain network efficiency, as demonstrated also in 
simulation frameworks87, graph theory provides a powerful tool for exploring 
the relationship between connectome damage and clinical status. As for the 
mesoscale approach, this comes at the price of losing the specificity of 
localisation and biological substrate of the damage. From a methodological point 
of view, the connectomic approach is still undergoing intense development and 
lacks of agreement on several technical aspects, including how to optimally 
parcellate the cortex, how to run the tractography, how to weight the edges of 
the graph88 The connectomic approach, though, can capture subtle diffuse 
changes that spread across several functional and structural systems, 
independently of the source of damage of affected edges or nodes. 
 
(figure 4 approximately here) 
 
Conclusions: 
Current literature is providing a whole new set of techniques that have the 
potential of revealing the substrates of pathological changes in MS, and more 
generally in neurological diseases. These tend to be too demanding in terms of 
image acquisition and analysis to be exploited in large clinical studies, and often 
are not supported by sufficiently strong evidence of validity. Recent software and 
hardware developments, such as the development of fast acquisition schemes89 
and the availability of increasingly strong magnetic field gradients90, are likely to 
facilitate the clinical adoption of dMRI.  
From a microscopic point of view, while models are providing indices potentially 
specific to a microstructural characteristic, such as axonal density, in reality 
there is a coexistence of substrates influencing each other.  
Despite its current limitations, dMRI provides the added value of some level of 
multi-modal investigation of pathology (by providing a range of biologically 
meaningful indices). At the same time dMRI also offers the unique opportunity of 
interrogating damage from a multi-scale approach by combining microscopic, 
mesoscopic and macroscopic information.   
Clinically, if all pitfalls were to be overcome, dMRI could have the potential of 
providing complementary information to conventional imaging and clinical data 
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Figure 1. DTI maps in a patient with MS. (A) FLAIR scan showing the 
distribution of macroscopic lesions: (B) Mean diffusivity; (C) Radial diffusivity; 
(D) Fractional anisotropy. Note the diversity in the lesional tissue appearance in 
different maps. The red arrows point at the same lesion on the 3 maps.  
 
Figure 2. In-vivo q-space imaging in a patient with MS. (a) q-space 
probability (zero-filled), (b) q-space displacement (zero-filled), (c) Fractional 
anisotropy , (d) FLAIR, and (e) T1-weighted images. Reproduced from Assaf et 
al., 200245 with permission from John Wiley &Sons, Inc. 
 
Figure 3. Sketch of potential multiple damage of different sources affecting 
network edges in MS.  (a) Fully connected healthy network. A, B, C, D are the 
nodes and ab, ac, ad, bc, cd and bd are edges that can be characterised by 
different weights and properties. (b) Fully connected network attacked by 
several disease processes. Edges are either healthy or damaged to different 
extents. Changes at edge and node level will have a cumulative effect on the 
overall properties of the network. Graph metrics may be able to capture 
differences between the healthy and damaged networks, at the price of loosing 
the local specificity of tissue alterations. 
 
Figure 4. Whole-brain network comparison between patients with 
clinically isolated syndrome (CIS), patients with MS, and healthy controls 
(NC). The node sizes indicate the significance of between-group differences in 
the regional efficiency. (A) For the structural network (SC), nodes in blue showed 
reduced efficiency in CIS and MS patients compared with controls, and decreased 
efficiency in MS compared with CIS. (B) For the functional network (FC), nodes 
in red showed increased efficiency in CIS compared with controls and nodes in 
blue showed decreased efficiency in MS compared with CIS or 
controls.  Reproduced from Shu et al., 201682 with permission from Nature 
Publishing Group. 
 
